clinical trial · NCT07116967
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb·phase3·recruiting·n = 3,040
Plaque PsoriasisDeucravacitinibUstekinumab
brief summary
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
started
Sep 22, 2025
primary completion
Jan 16, 2031
completion
Jan 16, 2031
last updated
Apr 20, 2026
official title
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol